The total number of records retrieved from this search are 20. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_487	Virus nameAdenovirus	Virus strainOBP-301 (telomelysin)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineDS Pharma Biomedical	Origin of cell lineHuman osteosarcoma cell line	Cell lineMNNG/HOS	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayXTT assay	In-vitro virus concentration1 MOI	In-vitro result102% cancer cell viability (calculated as relative to mock-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedOBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27356624
IDOV_491	Virus nameAdenovirus	Virus strainOBP-301 (telomelysin)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineDS Pharma Biomedical	Origin of cell lineHuman osteosarcoma cell line	Cell lineMNNG/HOS	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayXTT assay	In-vitro virus concentration5 MOI	In-vitro result98% cancer cell viability (calculated as relative to mock-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedOBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27356624
IDOV_495	Virus nameAdenovirus	Virus strainOBP-301 (telomelysin)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineDS Pharma Biomedical	Origin of cell lineHuman osteosarcoma cell line	Cell lineMNNG/HOS	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayXTT assay	In-vitro virus concentration10 MOI	In-vitro result96% cancer cell viability (calculated as relative to mock-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedOBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27356624
IDOV_499	Virus nameAdenovirus	Virus strainOBP-301 (telomelysin)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineDS Pharma Biomedical	Origin of cell lineHuman osteosarcoma cell line	Cell lineMNNG/HOS	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayXTT assay	In-vitro virus concentration50 MOI	In-vitro result80% cancer cell viability (calculated as relative to mock-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedOBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27356624
IDOV_503	Virus nameAdenovirus	Virus strainOBP-301 (telomelysin)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineDS Pharma Biomedical	Origin of cell lineHuman osteosarcoma cell line	Cell lineMNNG/HOS	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayXTT assay	In-vitro virus concentration100 MOI	In-vitro result56% cancer cell viability (calculated as relative to mock-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedOBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27356624
IDOV_507	Virus nameAdenovirus	Virus strainOBP-301 (telomelysin)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	Immune gene insertion in viral genomeNo	Source of cell lineDS Pharma Biomedical	Origin of cell lineHuman osteosarcoma cell line	Cell lineMNNG/HOS	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayXTT assay	In-vitro virus concentration1 MOI	In-vitro result99% cancer cell viability (calculated as relative to mock-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedOBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27356624
IDOV_511	Virus nameAdenovirus	Virus strainOBP-301 (telomelysin)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	Immune gene insertion in viral genomeNo	Source of cell lineDS Pharma Biomedical	Origin of cell lineHuman osteosarcoma cell line	Cell lineMNNG/HOS	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayXTT assay	In-vitro virus concentration5 MOI	In-vitro result84% cancer cell viability (calculated as relative to mock-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedOBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27356624
IDOV_515	Virus nameAdenovirus	Virus strainOBP-301 (telomelysin)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	Immune gene insertion in viral genomeNo	Source of cell lineDS Pharma Biomedical	Origin of cell lineHuman osteosarcoma cell line	Cell lineMNNG/HOS	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayXTT assay	In-vitro virus concentration10 MOI	In-vitro result65% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedOBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27356624
IDOV_519	Virus nameAdenovirus	Virus strainOBP-301 (telomelysin)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	Immune gene insertion in viral genomeNo	Source of cell lineDS Pharma Biomedical	Origin of cell lineHuman osteosarcoma cell line	Cell lineMNNG/HOS	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayXTT assay	In-vitro virus concentration50 MOI	In-vitro result50% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedOBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27356624
IDOV_523	Virus nameAdenovirus	Virus strainOBP-301 (telomelysin)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	Immune gene insertion in viral genomeNo	Source of cell lineDS Pharma Biomedical	Origin of cell lineHuman osteosarcoma cell line	Cell lineMNNG/HOS	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayXTT assay	In-vitro virus concentration100 MOI	In-vitro result36% cancer cell viability (calculated as relative to mock-infected group), antagonist effect with drugs	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedOBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27356624
IDOV_527	Virus nameAdenovirus	Virus strainOBP-301 (telomelysin)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	Immune gene insertion in viral genomeNo	Source of cell lineDS Pharma Biomedical	Origin of cell lineHuman osteosarcoma cell line	Cell lineMNNG/HOS	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayXTT assay	In-vitro virus concentration1 MOI	In-vitro result83% cancer cell viability (calculated as relative to mock-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedOBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27356624
IDOV_531	Virus nameAdenovirus	Virus strainOBP-301 (telomelysin)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	Immune gene insertion in viral genomeNo	Source of cell lineDS Pharma Biomedical	Origin of cell lineHuman osteosarcoma cell line	Cell lineMNNG/HOS	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayXTT assay	In-vitro virus concentration5 MOI	In-vitro result77% cancer cell viability (calculated as relative to mock-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedOBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27356624
IDOV_535	Virus nameAdenovirus	Virus strainOBP-301 (telomelysin)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	Immune gene insertion in viral genomeNo	Source of cell lineDS Pharma Biomedical	Origin of cell lineHuman osteosarcoma cell line	Cell lineMNNG/HOS	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayXTT assay	In-vitro virus concentration10 MOI	In-vitro result60% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedOBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27356624
IDOV_539	Virus nameAdenovirus	Virus strainOBP-301 (telomelysin)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	Immune gene insertion in viral genomeNo	Source of cell lineDS Pharma Biomedical	Origin of cell lineHuman osteosarcoma cell line	Cell lineMNNG/HOS	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayXTT assay	In-vitro virus concentration50 MOI	In-vitro result45% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedOBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27356624
IDOV_543	Virus nameAdenovirus	Virus strainOBP-301 (telomelysin)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	Immune gene insertion in viral genomeNo	Source of cell lineDS Pharma Biomedical	Origin of cell lineHuman osteosarcoma cell line	Cell lineMNNG/HOS	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayXTT assay	In-vitro virus concentration100 MOI	In-vitro result35% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedOBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27356624
IDOV_547	Virus nameAdenovirus	Virus strainOBP-301 (telomelysin)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	Immune gene insertion in viral genomeNo	Source of cell lineDS Pharma Biomedical	Origin of cell lineHuman osteosarcoma cell line	Cell lineMNNG/HOS	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayXTT assay	In-vitro virus concentration1 MOI	In-vitro result65% cancer cell viability (calculated as relative to mock-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedOBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27356624
IDOV_551	Virus nameAdenovirus	Virus strainOBP-301 (telomelysin)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	Immune gene insertion in viral genomeNo	Source of cell lineDS Pharma Biomedical	Origin of cell lineHuman osteosarcoma cell line	Cell lineMNNG/HOS	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayXTT assay	In-vitro virus concentration5 MOI	In-vitro result60% cancer cell viability (calculated as relative to mock-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedOBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27356624
IDOV_555	Virus nameAdenovirus	Virus strainOBP-301 (telomelysin)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	Immune gene insertion in viral genomeNo	Source of cell lineDS Pharma Biomedical	Origin of cell lineHuman osteosarcoma cell line	Cell lineMNNG/HOS	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayXTT assay	In-vitro virus concentration10 MOI	In-vitro result50% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedOBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27356624
IDOV_559	Virus nameAdenovirus	Virus strainOBP-301 (telomelysin)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	Immune gene insertion in viral genomeNo	Source of cell lineDS Pharma Biomedical	Origin of cell lineHuman osteosarcoma cell line	Cell lineMNNG/HOS	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayXTT assay	In-vitro virus concentration50 MOI	In-vitro result38% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedOBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27356624
IDOV_563	Virus nameAdenovirus	Virus strainOBP-301 (telomelysin)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	Immune gene insertion in viral genomeNo	Source of cell lineDS Pharma Biomedical	Origin of cell lineHuman osteosarcoma cell line	Cell lineMNNG/HOS	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayXTT assay	In-vitro virus concentration100 MOI	In-vitro result25% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedOBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27356624